Rising preference for personalized medicine and increasing prevalence of infectious diseases are attributed to fuel the growth of the global point-of-care molecular diagnostics market at a CAGR of 14.90% during the forecast period 2023 to 2030

Market Research Future (MRFR) has published a cooked research report on the “global point-of-care molecular diagnostics market”that contains the information from 2019 to 2030.

The point-of-care molecular diagnostics market is estimated to register a CAGR of 14.90% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the global point-of-care molecular diagnostics market— Abbott Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Cepheid (US), altona Diagnostics GmbH (Germany), Siemens Healthineers AG (Germany), Thermo Fisher Scientific, Inc. (US), ELITechGroup (France), Trinity Biotech plc (Ireland), and Others.

Market Highlights

The global point-of-care molecular diagnostics market is projected to register a CAGR of 14.90% during the forecast period and is estimated to reach USD 13.26 billion by 2030.

Point-of-care tests produce rapid, reliable results that aid in the identification and monitoring of acute infections or chronic diseases. These are primarily concerned with detecting a single pathogen. It also uses multiplex capabilities, including the simultaneous detection of two or more pathogens.

The rising preference for personalized medicine, as well as the increasing prevalence of infectious diseases, are propelling the global market for point-of-care molecular diagnostics forward. However, the shortages of skilled professionals are attributed to restraints on market growth. Nonetheless, it is anticipated that the increasing investment and funding to develop innovative point-of-care will create lucrative opportunities in the coming years.

Segment Analysis

The global point-of-care molecular diagnostics market has been segmented based on product & service, technology, application, and end user.

On the basis of product & service, the market is segmented into assays & kits, instruments & analyzers, and software & services. The assays & kits segment held the majority of the market in 2022 and software & services is attributed to be the fastest-growing segment during the forecast period.

Based on technology, the global point-of-care molecular diagnostics market has been segmented into RT-PCR, INAAT, and others. The INAAT segment is projected to be the fastest-growing segment during the forecast period.

On the basis of the application, the market is segmented into cancer, infectious diseases, hematology, endocrinology, and others. The cancer segment is projected to have the largest market share during the forecast period.

The global point-of-care molecular diagnostics market, based on end user, is segmented into hospitals & clinics, diagnostic centers, and others. Hospitals & clinics is estimated to hold the largest market share and diagnostic centers is projected to be the fastest growing in upcoming years.

Explore In-depth Details: Point of Care Molecular Diagnostics Market Research Report

Regional Analysis

The global point-of-care molecular diagnostics market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe point-of-care molecular diagnostics market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The point-of-care molecular diagnostics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World point-of-care molecular diagnostics market comprises of Middle East, Africa, and Latin America.

The North America point-of-care molecular diagnostics market is driving through the increasing prevalence of cancer, and infectious diseases, and strategic initiatives. For instance, in August 2022, Precision Diabetes, Inc. (US) and DxGen Corp. (US) agreed to launch Epithod AutoDx, a fully automated point-of-care (POC) analyzer to measure diabetes. This analyzer is user-friendly and easy to operate, making it suitable for point-of-care settings in places such as smaller laboratories, physician offices, outpatient clinics, and hospitals, which is driving the region’s market growth.

Moreover, the Europe market growing continuously owing to the increasing incidences of infectious diseases and a growing preference for personalized medicine to treat chronic diseases such as diabetes and obesity.

Furthermore, the Asia-Pacific market is growing rapidly as a result of the increasing prevalence of infectious diseases such as influenza and acquired immunodeficiency syndrome and the increasing prevalence of cardiovascular diseases. According to the Integrated Health Information Platform, there were 3038 influenza cases, including H3N2, in India as of March 2023, and influenza is rapidly spreading in India, which is a driving factor in market growth. 

Additionally, the rest of the world's market for point-of-care molecular diagnostics market is comprised of the Middle East, Africa, and Latin America. The region's point-of-care molecular diagnostics market is driven by factors such as increased infectious diseases rate and unhealthy lifestyles leading to obesity and diabetes.

Key Findings of the Study

• The global point-of-care molecular diagnostics market is expected to reach USD 13.26 billion by 2030, at a CAGR of 14.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the growing geriatric population and rising infectious diseases prevalence rate.


• Based on technology, the RT-PCR was attributed to holding the largest market in 2022, with an approximate market share of 45–55%.

Abbott Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), Cepheid (US), altona Diagnostics GmbH (Germany), Siemens Healthineers AG (Germany), Thermo Fisher Scientific, Inc. (US), ELITechGroup (France), and Trinity Biotech plc (Ireland) are the key market players.